menu
Karel Petrak

Karel Petrak

New concepts in drug targeting

location_on Houston, Texas Area

Chief Scientific Officer at NangioTx

VP for R&D at Agennix Inc.

Awards Earned:

0

0

0

0

0

Level: LEVEL 03 (12mo pts: 572 pts)

Lifetime points: 1021 pts View details

Thought Leadership:

% performance based on average of all engagements

Selected: % of applied

33%

Recognized: Contributions valued by peers

0%

Peer Support: Percentile of active participants

0%

Profile

Summary

Accomplishments:
- generated safety, toxicity and efficacy preclinical data, and designed several clinical studies (mucositis, necrotizing enterocolitis, head and neck cancer, severe sepsis) which showed talactoferrin to be effective in Phase 2 clinical studies. - raised $10+ MM federal funds to support the above clinical studies.

- led development of gene-based products for asthma, rheumatoid arthritis, and transplant rejection project funded by Syntex (later Roche) with a total budget of $17 million. I filed patents for the electroporation and ultrasonic-nebulization technologies for gene delivery.

- managed a testing laboratory and a data management/statistics group (staff of 20, monitoring 5000+ studies) and streamlined stability testing to achieve 20% reduction of the overall work-volume and costs.

- developed self-assembling nanoparticles that avoided recognition by the reticulo-endothelial system of the body – a property essential for a systemic delivery of site-specific systems.

- developed and patented new photographic and electro resist materials, a surfactant-specific electrode, and a method for measuring diffusion of oxygen through coated polymer layers. I also developed polymer/polymer interactions and phase separation systems which found a major practical application in the company’s coating technology.

Published over 100 scientific publications and patents.

Specialties: Project leadership and management in all aspects of drug research and development.

Experience

Chief Scientific Officer

NangioTx

February 2016 - Present

CSO guiding the company towards a successful submission of an Investigational New Drug designation for the company's lead compound.

In addition, is available for consulting services in the area of drug development and drug delivery, with special emphasis on site-selective / targeted delivery, covering pre-clinical, clinical and product-development phases.

VP for R&D

Agennix Inc.

July 2000 - September 2010

Leading development of a new immunomodulating-protein product from preclinical to successful Phase 2 clinical study in adult and neonatal sepsis.

Skills

Research 19
pharma 18
Drug Development 10
CRO 10
FDA 8
Drug Discovery 6
Leadership 5
Clinical Trials 5
Pharmaceutical Industry 4
MD 4
Validation 4
Energy 3
Cancer 2
Healthcare 2
Innovation 2
Problem Solving 1
Energy Policy Design and Evaluation
Energy Accounting
Pharmaceutical Manufacturing
Supply Chain
Pharmacy Operations
Assay Development
Health Information Systems
Healthcare Analytics
Oncology
Insurance
Pharmacy Benefit Management
Allied Health
global energy
Climate Change
Pharmaceutical Development
Climate Change & Environmental Policy
Drug Delivery
Drug targeting
Developing drugs suitable for site-specific delivery
Pre-clinical and clinical study design
Project development and management
Knowledge Management
Grant administration from project design to successful grant application
Healthcare Management
Strategic Planning
R&D
Quality Management
Translational Research
Lactoferrins & recombinant human lactoferrin
Characterization - chemical & physical: drugs, proteins, polymers
Biotechnology
Structure versus property relationship
Creative writing for success
Clinical Development
Start-ups
Biopharmaceuticals
Clinical Research
Lifesciences
GLP
Regulatory Affairs
Strategy
Pharmaceutics
Vaccines
Immunology
Technology Transfer
21 CFR Part 11
GMP
Infectious Diseases
Genomics
Commercialization
Molecular Biology

Industries

Pharmaceutical Manufacturing
Insurance

Activities